companydata.dkAdaptVac ApS: Financial statements 2024
CVR: 38732730
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 8,392,621 and a net result of DKK 1,714,349 compared with DKK 50,885,920 the year before. That is a decrease of 87.9% compared with the year before. Equity amounted to DKK 17,862,361. The solvency ratio was 89.2%. The company had 6 employees in the financial year.
- Gross Profit
- 8,392,621 kr.
- Profit/Loss
- 1,714,349 kr.
- Equity
- 17,862,361 kr.
- Total Assets
- 20,035,991 kr.
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 8.4 mio. | 1.7 mio. | 17.9 mio. | 6 |
| 2023 | - | 69.2 mio. | 50.9 mio. | 58.6 mio. | 6 |
| 2022 | - | -1.6 mio. | -4.8 mio. | 7.8 mio. | 6 |
| 2021 | - | 1.3 mio. | -1.8 mio. | 12.6 mio. | 5 |
| 2020 | - | 20.2 mio. | 15.5 mio. | 15.3 mio. | 3 |
How creditworthy is AdaptVac ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
AdaptVac ApS has published its annual report for 2023. Gross profit came to DKK 69,205,437, and the net result was DKK 50,885,920.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity amounted to DKK 10,808,696.